Global Somatic Cancer Mutation Testing Market Size & Trends

Global Somatic Cancer Mutation Testing Market Size & Trends

According to a new market research report published by Global Market Estimates, the Global Somatic Cancer Mutation Testing Market is projected to grow at a CAGR of 9.5% from 2022 to 2027.

The growing demand for clinical diagnostic testing for cancer mutations, increasing adoption of NGS in cancer diagnostics, growing demand for genetic mutation diagnostics, and the advancements in medical diagnostic technologies have been instrumental in the rapid development of the global somatic cancer mutation testing market.

Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and indepth TOC on “Global Somatic Cancer Mutation Testing Market - Forecast to 2027’’ https://www.globalmarketestimates.com/market-report/somatic-cancer-mutationtesting-market-3886

By Product (Instruments & Platforms, Reagents & Other Consumables), By Type (Hematological Cancer Profiling, Solid Tumor Profiling), By Technology (NGS, PCR & RT PCR, IHC, Others), By Indication (Breast Cancer, Ovarian, Prostate, Lung Cancer, Others),

By Region (North America, Asia Pacific, Central & South America, Europe, and the Middle East & Africa), End-User Landscape Analysis, Company Market Share Analysis, and Competitor Analysis

Key Market Insights 

As per the indication outlook, the breast cancer segment is expected to be the largest

 

segment in the somatic cancer mutation testing market from 2022 to 2027 The Asia Pacific region is analyzed to be the fastest-growing segment in the market United States has the largest share in the North American market during the forecast



period of 2022-2027.

As per the type, the hematological cancer profiling segment is expected to be the largest segment in the somatic cancer mutation testing market from 2022 to 2027



Thermo Fisher Scientific, Inc., Illumina, Inc., Invitae Corporation, F. Hoffmann-La Roche Ltd., MedGenome, CENTOGENE N.V., Myriad Genetics, Inc., eviCore healthcare, CeGaT GmbH, QIAGEN, among others, are key players in the global somatic cancer mutation testing market.

Product Outlook (Revenue, USD Billion, 2022-2027) 

Instruments & Platforms



Reagents & Other Consumables

Type Outlook (Revenue, USD Billion, 2022-2027) 

Hematological Cancer Profiling



Solid Tumor Profiling

Technology Outlook (Revenue, USD Billion, 2022-2027) 

NGS



PCR & RT PCR



IHC



Others

Indication Outlook (Revenue, USD Billion, 2022-2027) 

Breast Cancer



Ovarian



Prostate



Lung Cancer



Others

Regional Outlook (Revenue, USD Billion, 2022-2027) North America   

The U.S. Canada Mexico

Europe       

Germany UK France Spain Italy Netherlands Rest of Europe

Asia Pacific          

China India Japan South Korea Thailand Indonesia Malaysia Singapore Vietnam Rest of APAC

Central & South America    

Brazil Argentina Chile Rest of CSA

Middle East & Africa     

Saudi Arabia UAE Israel South Africa Rest of MEA

Contact: Yash Jain Email address: yash.jain@globalmarketestimates.com

Phone Number: +1 6026667238